Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 07, 2014 01:49 ET | Source: H. Lundbeck A/S

Continued solid growth of 36% in New Products - now contributing 27% of revenue

New Products on track and reached DKK 1,901 million in revenue driven by Abilify Maintena®, Onfi®, Treanda® and the recent launch of Brintellix® US revenue was DKK 1,626 million, an...
July 14, 2014 02:30 ET | Source: H. Lundbeck A/S

Otsuka og Lundbeck indsender registreringsansøgning for brexpiprazol til behandling af skizofreni og til kombinationsbehandling af svær depression

Registreringsansøgningen understøttes af syv afsluttede kliniske fase 2 eller 3 studier i de angivne indikationer Det kliniske udviklingsprogram omfattede mere end 6.500 personer, herunder...
July 14, 2014 02:30 ET | Source: H. Lundbeck A/S

Otsuka and Lundbeck submit New Drug Application for brexpiprazole for the treatment of schizophrenia and as adjunctive therapy for the treatment of major depression

The NDA is supported by seven completed clinical Phase 2 or 3 studies in proposed indications Clinical development program included more than 6,500 individuals, including more than 5,300 who...
June 27, 2014 11:35 ET | Source: H. Lundbeck A/S

Lundbeck provides update on the development program for desmoteplase

The first of two phase III clinical studies (DIAS-3) in patients with acute ischaemic stroke treated in the time-window 3-9 hours after stroke onset did not meet the primary endpoint When...
June 27, 2014 11:35 ET | Source: H. Lundbeck A/S

Lundbeck opdaterer vedrørende udviklingsprogrammet for desmoteplase

Det første af to kliniske fase III-studier af patienter med akut iskæmisk slagtilfælde behandlet i tidsrummet 3-9 timer efter et slagtilfælde opfyldte ikke det primære effektmål Ved analyse...
June 26, 2014 00:00 ET | Source: H. Lundbeck A/S

Nye forskningsresultater viser, at Brintellix® (vortioxetin) er effektivt i behandling af asiatiske patienter, der lider af depression

Valby, 2014-06-26 06:00 CEST (GLOBE NEWSWIRE) -- H. Lundbeck A/S (Lundbeck) har offentliggjort resultater af SOLUTION-forsøget udført med asiatisk patienter, der lider af Major Depressive Disorder...
June 26, 2014 00:00 ET | Source: H. Lundbeck A/S

New study results demonstrate Brintellix® (vortioxetine) is efficacious in Asian patients suffering from depression

Valby, 2014-06-26 06:00 CEST (GLOBE NEWSWIRE) -- H. Lundbeck A/S (Lundbeck) announced results of the SOLUTION trial conducted in Asian patients suffering from Major Depressive Disorder (MDD), more...
June 23, 2014 06:33 ET | Source: H. Lundbeck A/S

Lundbeck har succesfuldt afsluttet købstilbuddet på Chelsea Therapeutics

Fusionen forventes afsluttet i dag, og 62,5 % af de udestående aktier er overdraget og 16,1 % af de udestående aktier er omfattet af ”meddelelse om garanteret overdragelse” Ved opkøbet af...
June 23, 2014 06:33 ET | Source: H. Lundbeck A/S

Lundbeck successfully completes tender offer for Chelsea Therapeutics

Merger expected to close today, 62.5% of outstanding shares tendered and Notices of Guaranteed Delivery delivered for 16.1% of outstanding shares By acquiring Chelsea Therapeutics, Lundbeck...
June 17, 2014 09:00 ET | Source: H. Lundbeck A/S

Brintellix® demonstrated a statistically significantly superior improvement compared to escitalopram in improving sexual functioning in well treated patients suffering from depression and experiencing treatment-emergent sexual dysfunction

Valby, 2014-06-17 15:00 CEST (GLOBE NEWSWIRE) -- H. Lundbeck A/S (Lundbeck) today will present results about sexual functioning from a head-to-head study of Brintellix® (vortioxetine) vs....